Page last updated: 2024-12-05

atropine sulfate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Atropine sulfate is a synthetic derivative of atropine, a naturally occurring alkaloid found in the deadly nightshade plant (Atropa belladonna). It is a potent anticholinergic, meaning it blocks the action of acetylcholine, a neurotransmitter responsible for muscle contractions and various bodily functions. Atropine sulfate is synthesized by reacting atropine with sulfuric acid. It is primarily used in medicine to treat bradycardia (slow heart rate), organophosphate poisoning, and as an antidote for certain medications. It is also used in ophthalmology to dilate pupils for eye examinations and surgery. Atropine sulfate is studied extensively due to its diverse pharmacological effects and potential applications in various medical fields, including treatment of conditions like asthma, Parkinson's disease, and urinary incontinence. Its importance lies in its ability to antagonize the effects of acetylcholine, leading to a range of therapeutic benefits. However, it also has significant side effects, including dry mouth, blurred vision, and increased heart rate. Hence, its use is strictly regulated and monitored.'

Cross-References

ID SourceID
PubMed CID12310714
CHEMBL ID2146146
SCHEMBL ID31132
MeSH IDM0001935
PubMed CID3661
CHEMBL ID9751
CHEBI ID104243
SCHEMBL ID2813
MeSH IDM0001935

Synonyms (140)

Synonym
atropine sulfate anhydrous
atropine sulphate
nsc-26671
atropine sulfate
atropinsulfat
atropt
atropine sulfate monohydrate
atropine sulfate hydrate
benzeneacetic acid, alpha-(hydroxymethyl)- (3-endo)-8-methyl-8-azabicyclo(3.2.1)oct-3-yl ester, sulfate (1:1) (salt)
2472-17-5
atropine, sulfate (1:1)
CHEMBL2146146
nsc-755889
atropini sulfas
benzeneacetic acid, .alpha.-(hydroxymethyl)- (3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl ester, sulfate (1:1) (salt)
SCHEMBL31132
VJFQPODMEGSXHC-RIMUKSHESA-N
[(1r,5s)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate;sulfuric acid
51-53-6
benzeneacetic acid, alpha-(hydroxymethyl)- (3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl ester, labeled with tritium, sulfate (2:1) (salt)
AC-15995
AKOS009031432
CHEMBL9751
1.alpha.h,5.alpha.h-tropan-3.alpha.-ol (.+/-.)-tropate (ester)
benzeneacetic acid, .alpha.-(hydroxymethyl)- 8-methyl-8-azabicyclo[3.2.1]oct-3-yl ester endo-(.+/-.)-
DIVK1C_000558
KBIO1_000558
SDCCGMLS-0066623.P001
EU-0100567
SPECTRUM_001159
SPECTRUM4_001813
benzeneacetic acid, .alpha.-(hydroxymethyl)-, 8-methyl-8-azabicyclo[3.2.1]oct-3-yl ester, [3(s)-endo]-
BPBIO1_000386
OPREA1_442738
IDI1_000558
LOPAC0_000567
LOPAC0_000042
BSPBIO_000350
PRESTWICK3_000565
PRESTWICK2_000565
SPECTRUM5_000545
SMP1_000031
UPCMLD-DP018:001
AB00514677
UPCMLD-DP018
NCGC00093951-04
NCGC00161600-02
NCGC00094699-02
NCGC00094699-01
NCGC00161600-01
KBIOGR_002450
KBIOSS_001639
KBIO2_006775
KBIO2_004207
KBIO3_001374
KBIO2_001639
NINDS_000558
SPECTRUM3_000307
SPBIO_002569
PRESTWICK1_000565
PRESTWICK0_000565
SPBIO_000048
SPECTRUM2_000094
BSPBIO_001874
NCGC00093951-02
NCGC00093951-01
NCGC00161600-03
NCGC00093951-03
NCGC00015026-03
H 9002 ,
A0754
NCGC00015026-12
NCGC00015026-13
L001264
H0450
CHEBI:104243
HMS3261B16
CCG-204138
cas_51-55-8
atropine,(-)
bdbm86231
nsc_3661
NCGC00015026-05
NCGC00015026-08
NCGC00015026-04
NCGC00015026-07
NCGC00015026-11
NCGC00015026-10
NCGC00015026-09
NCGC00015026-06
NCGC00015026-14
STL374102
LP00567
HMS3372F19
HMS3373B22
BBL033747
(8-methyl-8-azabicyclo[3.2.1]oct-3-yl) 3-hydroxy-2-phenyl-propanoate
SCHEMBL2813
benzeneacetic acid, .alpha.-(hydroxymethyl)-, 8-methyl-8-azabicyclo[3.2.1]oct-3-yl ester, [3(s)-endo]-, sulfate (2:1) (salt)
tox21_500567
NCGC00261252-01
Q-200659
.alpha.-(hydroxymethyl)benzeneacetic acid 8-methyl-8-azabicyclo(3.2.1)oct-3-yl ester, endo-
(.+/-.)-atropine
(.+/-.)-tropyl tropate
tropic acid, 3-.alpha.-tropanyl ester
benzeneacetic acid, .alpha.-(hydroxymethyl)- (3-endo)-8-methyl-8-azabicyclo(3.2.1)oct-3-yl ester
1-.alpha.-h,5-.alpha.-h-tropan-3-.alpha.-ol (.+/-.)-tropate
8-methyl-8-azabicyclo[3.2.1]oct-3-yl tropate #
atropisol (salt/mix)
1.alpha.h,5.alpha.h-tropan-3.alpha.-ol (.+/-.)-tropate
2-phenylhydracrylic acid 3-.alpha.-tropanyl ester
(.+/-.)-hyoscyamine
.beta.-phenyl-.gamma.-oxypropionsaeure-tropyl-ester
AB00514677_07
3-hydroxy-2-phenylpropanoic acid (8-methyl-8-azabicyclo[3.2.1]octan-3-yl) ester
Q27181620
sr-01000075162
SR-01000075162-1
l-hyoscyamine, analytical standard
l-hyoscyamine, >=98% (tlc), powder
HMS3652A17
SR-01000075162-12
SR-01000075162-2
SR-01000075162-13
SBI-0050031.P005
(8-methyl-8-azabicy-clo[3.2.1]oct-3-yl) 3-hydroxy-2-phenylpropanoate
l-hyoscyamine (sulfate)
VS-12248
8-methyl-8-azabicyclo[3.2.1]octan-3-yl 3-hydroxy-2-phenylpropanoate
DTXSID00858967
8-methyl-8-azabicyclo[3.2.1]oct-3-yl alpha-(hydroxymethyl)benzeneacetate
83454-31-3
BRD-A93739713-065-03-5
SDCCGSBI-0050031.P007
NCGC00015026-21
NCGC00015026-22
daturine (sulfate)
D88314
CS-0526746

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
tropane alkaloid
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (10)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency8.91250.003245.467312,589.2998AID2517
thioredoxin reductaseRattus norvegicus (Norway rat)Potency1.99530.100020.879379.4328AID588453
GLS proteinHomo sapiens (human)Potency5.62340.35487.935539.8107AID624146
EWS/FLI fusion proteinHomo sapiens (human)Potency18.06840.001310.157742.8575AID1259252; AID1259253; AID1259255; AID1259256
arylsulfatase AHomo sapiens (human)Potency2.39341.069113.955137.9330AID720538
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency0.00950.035520.977089.1251AID504332
Bloom syndrome protein isoform 1Homo sapiens (human)Potency1.41250.540617.639296.1227AID2364; AID2528
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency12.58930.01789.637444.6684AID588834
lamin isoform A-delta10Homo sapiens (human)Potency35.48130.891312.067628.1838AID1459
Inositol monophosphatase 1Rattus norvegicus (Norway rat)Potency14.12541.000010.475628.1838AID1457
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (88)

Assay IDTitleYearJournalArticle
AID333859Phototoxicity against Pseudomonas fluorescens at 100 ug/disk after irradiation with W/m'2 UV light
AID333878Phototoxicity against Staphylococcus aureus at 100 ug/disk in dark
AID176295Antiulcer activity in male Wistar rats for 50% inhibition of stress induced gastric lesions after intraduodenal administration.1982Journal of medicinal chemistry, Aug, Volume: 25, Issue:8
Pyridazinones. 1. Synthesis and antisecretory and antiulcer activities of thio amide derivatives.
AID333884Phototoxicity against Candida albicans at 100 ug/disk in dark
AID1123636Antagonist activity at muscarinic acetylcholine receptor in guinea pig ileum assessed as inhibition of acetylcholine-induced contraction1979Journal of medicinal chemistry, Jan, Volume: 22, Issue:1
Structure-activity relationship in a new series of atropine analogues. 1. N,N'-Disubstituted 6,7-diazabicyclo[3.2.2]nonane derivatives.
AID1131020Antidotal effect in hybrid CC57 mouse assessed as protection against sarin-induced poisoning by measuring sarin approximate lethal dose at 37.5 mg/kg, ip dosed 1.5 mins after sarin challenge and measured after 24 hrs (Rvb = 460 ug/kg)1979Journal of medicinal chemistry, Nov, Volume: 22, Issue:11
Antidotes or organophosphate poisoning. 2. Thiadiazole-5-carboxaldoximes.
AID26355pKa value was determined1990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
Synthesis and biological evaluation of new antimuscarinic compounds with amidine basic centers. A useful bioisosteric replacement of classical cationic heads.
AID333860Phototoxicity against Pseudomonas fluorescens at 100 ug/disk in dark
AID524794Antiplasmodial activity against Plasmodium falciparum GB4 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1131016Antidotal effect in hybrid CC57 mouse assessed as protection against sarin-induced poisoning by measuring sarin LD50 at 37.5 mg/kg, ip dosed 1.5 mins after sarin challenge and measured after 24 hrs (Rvb = 229 ug/kg)1979Journal of medicinal chemistry, Nov, Volume: 22, Issue:11
Antidotes or organophosphate poisoning. 2. Thiadiazole-5-carboxaldoximes.
AID133063Percent inhibition of the charcoal meal transfer in mice(100 mg/kg).1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Synthesis and spasmolytic activities of 2-(1,2-benzisoxazol-3-yl)-3-[[omega-(dialkylamino)alkoxy]phenyl]acrylonitriles.
AID333872Phototoxicity against Streptococcus faecalis at 100 ug/disk in dark
AID1123638Toxicity in ip dosed mouse1979Journal of medicinal chemistry, Jan, Volume: 22, Issue:1
Structure-activity relationship in a new series of atropine analogues. 1. N,N'-Disubstituted 6,7-diazabicyclo[3.2.2]nonane derivatives.
AID176294Antiulcer activity in male Donry rat for 50% inhibition of aspirin induced gastric lesions after intraduodenal administration.1982Journal of medicinal chemistry, Aug, Volume: 25, Issue:8
Pyridazinones. 1. Synthesis and antisecretory and antiulcer activities of thio amide derivatives.
AID333877Phototoxicity against Staphylococcus aureus at 100 ug/disk after irradiation with W/m'2 UV light
AID333853Phototoxicity against Pseudomonas aeruginosa at 100 ug/disk after irradiation with W/m'2 UV light
AID79532Inhibitory effect on the response of isolated ileum to transmural electrical stimulation in guinea pig (anti-TMS activity) was determined1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Synthesis and spasmolytic activities of 2-(1,2-benzisoxazol-3-yl)-3-[[omega-(dialkylamino)alkoxy]phenyl]acrylonitriles.
AID333865Phototoxicity against Bacillus subtilis at 100 ug/disk after irradiation with W/m'2 UV light
AID697852Inhibition of electric eel AChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID1131019Antidotal effect in hybrid CC57 mouse assessed as therapeutic ratio for protection against sarin-induced poisoning by measuring sarin LD50 at 37.5 mg/kg, ip dosed 1.5 mins after sarin challenge and measured after 24 hrs relative to sarin alone treated mou1979Journal of medicinal chemistry, Nov, Volume: 22, Issue:11
Antidotes or organophosphate poisoning. 2. Thiadiazole-5-carboxaldoximes.
AID524796Antiplasmodial activity against Plasmodium falciparum W2 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID333848Phototoxicity against Escherichia coli at 100 ug/disk in dark
AID333871Phototoxicity against Streptococcus faecalis at 100 ug/disk after irradiation with W/m'2 UV light
AID333854Phototoxicity against Pseudomonas aeruginosa at 100 ug/disk in dark
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID1150245Antidotal activity in ip dosed male mouse assessed as inhibition of tetraethylpyrophosphate-induced intoxication drug administered 5 mins prior to subcutaneously administration of 3 X LD50 of TEPP in presence of 25 mg/kg atropine sulfate1976Journal of medicinal chemistry, Jul, Volume: 19, Issue:7
Quaternary pilocarpine derivatives as potential acetylcholine antagonists. 2. Alterations in the lactone and imidazole moieties.
AID176449Percent inhibition of gastric antisecretory activity in the pylorus-ligated rat at a dose of 100 mg/kg administered intraduodenally1982Journal of medicinal chemistry, Aug, Volume: 25, Issue:8
Pyridazinones. 1. Synthesis and antisecretory and antiulcer activities of thio amide derivatives.
AID333890Phototoxicity against Saccharomyces cerevisiae at 100 ug/disk in dark
AID333847Phototoxicity against Escherichia coli at 100 ug/disk after irradiation with W/m'2 UV light
AID333883Phototoxicity against Candida albicans at 100 ug/disk after irradiation with W/m'2 UV light
AID697853Inhibition of horse BChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID476929Human intestinal absorption in po dosed human2010European journal of medicinal chemistry, Mar, Volume: 45, Issue:3
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
AID119056Compound was tested for the anticholinergic activity against tetrabenazine-treated mice; activity expressed as the pupil size at the dose of 1 mg/kg sc1986Journal of medicinal chemistry, Jan, Volume: 29, Issue:1
Neuroleptic activity of chiral trans-hexahydro-gamma-carbolines.
AID79504In vitro anticholinergic activity was determined by acetylcholine induced contraction of guinea pig ileum1980Journal of medicinal chemistry, Feb, Volume: 23, Issue:2
Synthesis and psychoanaleptic properties of new compounds structurally related to diphenhydramine.
AID333889Phototoxicity against Saccharomyces cerevisiae at 100 ug/disk after irradiation with W/m'2 UV light
AID79505In vitro antihistaminic activity was determined by histamine induced contraction of guinea pig ileum1980Journal of medicinal chemistry, Feb, Volume: 23, Issue:2
Synthesis and psychoanaleptic properties of new compounds structurally related to diphenhydramine.
AID1150239Inhibition of acetylcholine-induced contraction in guinea pig ileum at 0.03 ug/ml1976Journal of medicinal chemistry, Jul, Volume: 19, Issue:7
Quaternary pilocarpine derivatives as potential acetylcholine antagonists. 2. Alterations in the lactone and imidazole moieties.
AID79530Inhibitory effect on the response of isolated ileum to acetylcholine (anti-ACh activity) in guinea pig was determined1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Synthesis and spasmolytic activities of 2-(1,2-benzisoxazol-3-yl)-3-[[omega-(dialkylamino)alkoxy]phenyl]acrylonitriles.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1508628Confirmatory qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1508627Counterscreen qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: GLuc-NoTag assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1508629Cell Viability qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (28)

TimeframeStudies, This Drug (%)All Drugs %
pre-19907 (25.00)18.7374
1990's1 (3.57)18.2507
2000's3 (10.71)29.6817
2010's10 (35.71)24.3611
2020's7 (25.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 82.65

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index82.65 (24.57)
Research Supply Index2.83 (2.92)
Research Growth Index5.29 (4.65)
Search Engine Demand Index139.63 (26.88)
Search Engine Supply Index2.01 (0.95)

This Compound (82.65)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other13 (100.00%)84.16%
Other16 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]